Your browser doesn't support javascript.
loading
Rapamycin Combined with Cyclosporine in the Prevention of Acute Renal Allograft Rejection:Randomized Prospective Control Study / 中国药房
China Pharmacy ; (12)2005.
Article Dans Chinois | WPRIM | ID: wpr-528304
ABSTRACT

OBJECTIVES:

To evaluate the efficacy of rapamycin(RPM)oral liquid plus cyclosporine(CsA)on the preven?tion of early acute rejection after renal allograft.

METHODS:

20patients undergoing primary renal allografting were randomly divided into RPM trial group and Azathioprine(Aza)control group,10cases in each group,who were respectively assigned to receive CsA and adrenocortial hormones-based immunosuppression for6months,indexes including survival rates of recipients/kidneys,incidences of acute rejection and adverse reactions between2groups were compared.

RESULTS:

For the17patients who had finished6-month treatment,the survival rates(recipients/kidneys)were100%.Only2episodes of acute rejection occurred in one case in Aza group.Both groups had2cases of severe adverse episodes.

CONCLUSIONS:

The combined therapy pf RPM plus CsA is effective in the prevention of acute renal allograft rejection,and it can maintain renal function at a good level.Nevertheless,it may increase the hepatotoxicity of CsA.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: China Pharmacy Année: 2005 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: China Pharmacy Année: 2005 Type: Article